Jane Street
AVBP icon

Jane Street’s ArriVent BioPharma AVBP Stock Holding History

Jane Street’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Buy
+49,800
New +$1.12M ﹤0.01% 6214

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street's AVBP Position: Q1 2026 in Review

Jane Street reduced its ArriVent BioPharma (AVBP) stake by 83% in Q1 2026, selling an estimated $1.93M and leaving 17,658 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #8523.

Jane Street first reported a position in AVBP in Q1 2024 and has held it in 5 quarters since. The position peaked at $2.08M in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Jane Street held 17,658 shares of ArriVent BioPharma worth $407K as of Q1 2026.
  • Jane Street sold 85,597 ArriVent BioPharma shares in Q1 2026, an estimated $1.93M.
  • ArriVent BioPharma made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #8523 holding.
  • Jane Street first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 5 quarters since.
  • Jane Street's ArriVent BioPharma position peaked at $2.08M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.